Skip to main content
. 2022 May;43(5):458–464. doi: 10.15537/smj.2022.43.5.20220018

Table 3.

- Comparison of cardiovascular outcome of patients in both groups before and 6 months after treatment.

Variable Empagliflozin (n=45) Placebo (n=48) P-value
Cardiovascular death 1 (2.2) 2 (4.2) 0.598
Hospitalized due to unstable angina 2 (4.5) 4 (8.7) 0.433
Coronary revascularization 1 (2.2) 0 0.312

The numbers are presented as frequency (percentage).

Significance level: p<0.05.